Pfizer’s Bourla: State of US Presidential Transition Not ‘Ideal’ For Vaccine Rollout

Pfizer and BioNTech have accumulated enough safety data to submit an emergency use authorization, and Pfizer CEO Bourla says at the Stat Summit that he is ‘comfortable’ US distribution of the vaccine will go well despite the unusually complicated government transition.

Pfizer CEO Albert Bourla discussed the company's COVID-19 vaccine on 17 November • Source: STAT Summit

Pfizer Inc. CEO Albert Bourla said the current state of the US presidential transition is not the “ideal” situation for rolling out a massive COVID-19 vaccination campaign but remained “comfortable” that the distribution of the company’s vaccine, partnered with BioNTech SE, will go well.

President-elect Joe Biden and his transition team are right now limited in their ability to receive information from the current...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Distribution/Supply Chain

More from Compliance